RxDoctor Payments Data

Ann Flynn, MD

Gastroenterology · Salt Lake City, UTNPI 1386790988

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,250 of the $6,436 with a category attached, or 81.6%. AbbVie accounts for 97.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $6,329 and has fallen 98.7% since, to $84 in 2025.

$6,436in general payments, 2019–2025

Across 15 payments — averaging $429.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$80
  • Pfizer$31
  • Genentech, Inc.$23
$39,550in research payments, 2019–2025

Across 37 payments — averaging $1068.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$40K

What the payments were for

  • Consulting fees$5,25082%
  • Travel & lodging$72211%
  • Food & beverage$4337%
  • Education$310%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,436 in reported general payments places this provider in the 80th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$54,508
Medicare patients
206
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab76$2,145,928
RinvoqUpadacitinib17$143,279
Mesalamine20$24,992
Omeprazole125$1,782
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine27$1,744
Mesalamine ErMesalamine14$1,738
Budesonide DrBudesonide11$1,280
LoperamideLoperamide Hcl16$1,196
Azathioprine15$879
Klor-Con M20Potassium Chloride12$546
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg12$313
Pantoprazole Sodium12$168
Prednisone14$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$6,302$143,27917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 122 gastroenterology providers in Utah.

Other gastroenterology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →